Research progress in the PD-1/PD-L1 pathway and IL-17A in lymphomas | Yang | Aging Pathobiology and Therapeutics

Research progress in the PD-1/PD-L1 pathway and IL-17A in lymphomas

Li Yang, Xin Xu

Abstract


In recent years, the tumor microenvironment has become the focus of immunotherapy in patients with lymphoma, especially with increasing age. The programmed death 1 (PD-1) and programmed death 1 ligand (PD[1]L1) signaling pathway is an important mechanism of cancer immunomodulation, and abnormal activation in the tumor microenvironment shows that the PD-1/PD-L1 pathway may take part in the regulation of tumor immune escape. Interleukin-17A (IL-17A) is a pro-inflammatory cytokine that plays a crucial role in the lymphoma cancer microenvironment and has divided roles in both tumor growth and cancer elimination. Thus IL[1]17A is a potential target in cancer immunotherapy. Previous studies have shown that IL-17A up-regulates the expression of PD-L1 in cancers or in autoimmune diseases but whether there is an interaction or relationship between the PD-1/PD-L1 pathway and IL-17A in lymphoma has not yet been fully recognized. The aim of this review is to track the recent progress of the PD-1/PD-L1 pathway and IL-17A in lymphoma. A better understanding of the role of the PD-1/PDL1 pathway and IL-17A in the progression of lymphoma will help provide new therapeutic directions, especially in older patients.

Keywords: PD-1/PD-L1, IL-17A, lymphoma, tumor microenvironment, aging, immunotherapy




Subscribe to receive issue release notifications
and newsletters from journals